27 April 2023
Avacta Group plc
("Avacta" or the "Company" and, together with its subsidiary undertakings, the "Group")
First Patient Dosed in the US in Avacta's AVA6000 Phase 1 Clinical Study
Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, announces that the first patient has been dosed in the US under its Investigational New Drug (IND) Application in Avacta's phase 1 multi-centre trial evaluating the safety and tolerability of AVA6000, a novel tumour targeted form of doxorubicin and Avacta's first therapeutic product based on its proprietary pre|CISION™ technology.
The first patient in the US has been dosed in the dose-escalation study in patients with locally advanced or metastatic selected solid tumours, known to be FAP-positive, at the Memorial Sloan Kettering Cancer Center in New York.
For more information visit www.clinicaltrials.gov (NCT04969835).
Dr Alastair Smith, Chief Executive Officer, Avacta Group plc, commented:
"The US trial sites in New York and Seattle will play a key role, along with other sites in the UK and US, in this multi-centre trial both in the dose escalation phase and in the dose expansion phase which we expect to begin in the second half of the year.
"Dosing the first patient in the US is a key milestone and reflects the continuing excellent progress in the ALS-6000-101 clinical trial and the Therapeutics Division as a whole."
-Ends-
For further information from Avacta Group plc, please contact:
Avacta Group plc
Alastair Smith, Chief Executive Officer
Tony Gardiner, Chief Financial Officer
Michael Vinegrad, Group Communications Director
Tel: +44 (0) 1904 21 7070
Stifel Nicolaus Europe Limited (Nomad and Broker)
Nicholas Moore / Nick Adams / Samira Essebiyea / Nick Harland / Dhiren Suares / William Palmer-Brown
Tel: +44 (0) 207 710 7600
FTI Consulting (Financial Media and IR)
Simon Conway / Alex Shaw
Tel: +44(0) 203 727 1000
Zyme Communications(Trade and Regional Media)
Lily Jeffery
Tel: +44 (0)7891 477 378
About Avacta Group plc - www.avacta.com
Avacta Group plc is a life sciences company working to improve people's health and well-being through innovative oncology drugs and powerful diagnostics. Operating through two divisions, Diagnostics and Therapeutics, the Group's mission is to provide professionals and consumers with solutions that improve healthcare, fitness and well-being.
Avacta'sTherapeutics Division , a clinical stage oncology drug innovator, is building a wholly owned pipeline of novel Affimer® immunotherapies and pre|CISION™ tumour targeted chemotherapies. This approach is designed to address the lack of a durable response to current cancer immunotherapies experienced by most patients and reduce the severe systemic toxicities caused by chemotherapies. There are five programmes in the pipeline as well as several global research collaborations and licensing partnerships. Avacta's lead programme, AVA6000, is a pre|CISION™ tumour-targeted form of the established chemotherapy doxorubicin. AVA6000 is in Phase I clinical trials in patients with locally advanced or metastatic selected solid tumours.
The Affimer® platform is an alternative to antibodies that has been designed to address many of the drawbacks of antibodies which, despite their shortcomings, currently dominate the immuno-diagnostics and immuno-therapeutics markets.
The pre|CISION™ tumour targeting platform can be used to modify a chemotherapy in order to selectively release the active drug in tumour tissue thereby reducing the systemic exposure that causes damage to healthy tissues. pre|CISION™ modified chemotherapies are designed to reduce the side effects and improve the overall safety and therapeutic potential of these powerful anti-cancer treatments.
Avacta'sDiagnostics Division develops and supplies a broad range of in-vitro diagnostic (IVD) solutions. The Division is growing rapidly through an M&A strategy to deliver a global scale IVD business providing market leading solutions for healthcare professionals and consumers to inform treatment and monitor health and well-being. In October 2022, Avacta acquired Launch Diagnostics which serves the hospital pathology laboratory market in the UK and Europe. Avacta Diagnostic's research and development centre in Wetherby, UK uses its proprietary Affimer® platform to differentiate immunodiagnostic products to provide marketing leading performance.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. ENDRESFLFSTSIIRFIV
==